Dutch Unit Of Centocor Expanding
Netherlands-based Centoco, a unit of US biotechnology company Centocor,is to invest 60 million guilders ($31.4 million) in the extension of production facilities at Leyden. The construction of a new building has recently started, and this will lead to the creation of an additional 60 jobs.
Centoco says it is active in developing genetic tests as well as drugs and, for the first time, now avails itself of strategic alliances with multinational pharmaceutical companies for marketing and sales of its products.
Examples of this are the agreement to commercialize the Centocor antiplatelet monoclonal antibody ReoPro with Eli Lilly, and Panorex, another MAb, which will be launched in cooperation with Glaxo Wellcome, local sources report.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze